COMMUNIQUÉS West-GlobeNewswire

pHemmePure Claims Evaluated: Feminine UTI Balance Formula for Vaginal pH Support by Board-Certified Urologist
22/04/2026
pHemmePure outlines its feminine balance supplement approach, full ingredient disclosure, and urinary tract wellness positioning for women over 35 seeking daily pH support in 2026 New York, NY, April 21, 2026 (GLOBE [...]
Curiox Biosystems Signs Master Software License Agreement for Enterprise-Scale Pluto Code Deployment
22/04/2026
First master licensing framework for Pluto Code enables a global pharmaceutical organization to expand centrifuge-free automation across its liquid-handling infrastructure without repeated contracting WOBURN, Mass., [...]
Triple Green Farms CBD Gummies Claims Evaluated: The Best CBD Gummy Formula on the Market Under Investigation
22/04/2026
A 2026 informational report on Triple Green Farms CBD Gummies' full spectrum hemp extract formula, how the endocannabinoid system works, what published CBD research supports, pricing and guarantee terms, and what adults [...]
RNK Health NAD+ Longevity Therapy Claims Evaluated: The Clinician-Guided NAD Injections & Medication Protocol
22/04/2026
An informational overview of how RNK Health structures its at-home NAD+ injection program for 2026, including telehealth eligibility, compounded medication protocols, pricing from $129/mo, and what to know about [...]
OPKO Health to Report First Quarter 2026 Financial Results on April 28, 2026
21/04/2026
MIAMI, April 21, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended March 31, 2026 after the close of the U.S. financial markets on [...]
Revolution Medicines to Present Updated Phase 1/2 Clinical Data for Daraxonrasib in First Line Metastatic Pancreatic Cancer Across Monotherapy and Combination Cohorts at the 2026 AACR Annual Meeting
21/04/2026
REDWOOD CITY, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today [...]
Resolutions of the Annual General Meeting 2026 of Bavarian Nordic A/S
21/04/2026
COPENHAGEN, Denmark, April 21, 2026 – Bavarian Nordic A/S (OMX: BAVA) today held the Annual General Meeting with the following results: The Annual Report for 2025 was adopted. The Board of Directors’ proposal to [...]
Panakeia Unveils Landmark Metabolic and Pathway Activation Data in Cancers at AACR 2026
21/04/2026
CAMBRIDGE, UK — April 21, 2026 — Panakeia (“the Company”), the world’s first in silico multi-omics company, today unveiled landmark pathway activation data in cancers at the American Association for Cancer Research ( [...]
Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026
21/04/2026
ZW191 demonstrates encouraging anti-tumor activity in heavily pretreated ovarian and endometrial cancers, regardless of FRα expression Confirmed objective response rate (cORR) of 61% at doses 6.4-9.6 mg/kg in platinum [...]
BBOT Presents Preclinical Data Showing RAS:PI3Kα Breaker BBO-10203 Inhibits PI3Kα/AKT Signaling in HER2AMP Models at the AACR Annual Meeting 2026
21/04/2026
BBO-10203 physically and allosterically disrupts the interaction between RAS and PI3Kα, leading to signaling inhibition without inhibiting the kinase activity of PI3Kα and with no observed hyperglycemia BBO-10203 [...]
Oculis Publishes Invitation to the Annual General Meeting
21/04/2026
ZUG, Switzerland, April 21, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis”), today published the invitation to the 2026 Annual General Meeting, which will be held on May 13, 2026 at Ochsen [...]
Cytokinetics to Announce First Quarter Results on May 5, 2026
21/04/2026
SOUTH SAN FRANCISCO, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report first quarter results on May 5, 2026 at 4:00 PM Eastern Time. [...]
Belite Bio Initiates Rolling Submission of New Drug Application to the U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease
21/04/2026
Belite expects to complete the new drug application submission in the second quarter of 2026 Rolling submission initiated under Breakthrough Therapy Designation SAN DIEGO, April 21, 2026 (GLOBE NEWSWIRE) -- Belite Bio [...]
Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting
21/04/2026
- Complete and durable regression and anti-tumor immune memory following treatment with FHD-909 (LY4050784) in combination with an anti-PD-1 antibody in preclinical syngeneic mouse models - Selective CBP degrader FHT- [...]
Aktis Oncology Announces Presentation of First Clinical Imaging and Dosimetry Data for AKY-2519 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
21/04/2026
AKY-2519, a miniprotein radioconjugate targeting B7-H3, to be featured in two poster presentations Data facilitate initial understanding of AKY-2519 biodistribution and predicted absorbed doses in tumors and normal [...]
Revolution Medicines to Present Preclinical Data on Innovative Mutant-Targeted Catalytic RAS(ON) Inhibitor at the 2026 AACR Annual Meeting
21/04/2026
Data highlight RM-055's ability to overcome resistance and provide deep, durable antitumor activity across preclinical models of pancreatic ductal adenocarcinoma, non-small cell lung cancer and colorectal cancer REDWOOD [...]
Oculis Publishes Invitation to the Annual General Meeting
21/04/2026
ZUG, Switzerland, April 21, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis”), today published the invitation to the 2026 Annual General Meeting, which will be held on May 13, 2026 at Ochsen [...]
Neuro Salt Ingredients Decoded: Deciphering the Difference Between Official Website Hype & Actual Health Benefits
21/04/2026
A 2026 informational overview of the Neuro Salt nerve health supplement — NeuroSalt supplement facts, botanical ingredient dosages, what the formula contains, how the company presents its research, and what to know [...]
Precede Biosciences Launches Precede Bio Insight™, a Genome-Wide Liquid Biopsy for Functional Tumor Biology at AACR 2026
21/04/2026
Precede Bio Insight debuts as a first-of-its-kind product enabling genome-wide inference of gene expression, pathway activity, and cell states from just 1 mL of plasma AACR studies demonstrate the ability to predict [...]

Pages